Serotonin and the GI tract

Current Gastroenterology Reports

Volumn 11, Issue 5, 2009, Pages 383-391

  Hasler, William L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; BUSPIRONE; CILANSETRON; CISAPRIDE; CITALOPRAM; DDP 225; FENFLURAMINE; KETANSERIN; MELATONIN; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; PHENTERMINE; PIBOSEROD; PLACEBO; PRUCALOPRIDE; PUMOSETRAG; RENZAPRIDE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SPASMOLYTIC AGENT; SUMATRIPTAN; TD 5108; TEGASEROD; TP 5108; UNCLASSIFIED DRUG; VENLAFAXINE;

ANGINA PECTORIS; BLOATING; CARCINOID SYNDROME; CELL GROWTH; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG UPTAKE; DYSPEPSIA; DYSPNEA; ENTEROCHROMAFFIN CELL; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL INFECTION; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; HEADACHE; HEART INFARCTION; HEARTBURN; HOT FLUSH; HUMAN; INTESTINE ISCHEMIA; INTESTINE PSEUDOOBSTRUCTION; IRRITABLE COLON; ISCHEMIC COLITIS; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; SLEEP DISORDER; ST SEGMENT DEPRESSION; STOMACH PARESIS; STROKE; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION;

ANIMALS; DRUG THERAPY, COMBINATION; ENTEROCYTES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 70349503442     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0058-7     Document Type: Review

References (48)

1. Tonini M: 5-Hydroxytryptamine effTct in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 2005, 17:637-642.
2. Van Lelyveld N, Ter Linde J, Schipper ME, Samsom M: Regional differences in expression of TPH-1, SERT, 5-HT3, and 5-HT4 receptors in the human stomach and duodenum. Neurogastroenterol Motil 2007, 19:342-348.
3. Holbrook JD, Gill CH, Zebda N, et al.: Characterization of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: Evolution, distribution and function. J Neurochem 2009, 108:384-396.
4. Gershon MD, Tack J: The seFotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397-414.
5. Kidd M, Modlin IM, Gustafsson BI, et al.: Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008, 295:G260-G272.
6. Chen JJ, Li ZS, Pan H, et al.: Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001, 21:6348-6361.
7. Tack J, Vanden Berghe P, Coulie B, et al.: Sumatriptan is an agonist at 5-HT1P receptors on myenteric neurons in the guinea pig gastric antrum. Neurogastroenterol Motil 2007, 19:39-46.
8. Bjornsson ES, Chey WD, Hooper F, et al.: Impaired gastrocolonic response and peristaltic reflex in slow transit constipation: Role of 5-HT3 pathways. Am J Physiol 2002, 283:G400-G407.
9. Camilleri M, Atanasova E, Carlson PJ, et al.: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002, 123:425-432.
10. Berman SM, Chang L, Suyenobu B, et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002, 123:969-977.
11. Sabate JM, Bouhassira D, Poupardin C, et al.: Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008, 20:134-141.
12. Beattie DT, Smith JA: Serotonin pharmacology in the gastrointestinal tract: A review. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:181-203.
13. Gwynne RM, Ellis M, Sjovall H, Bornstein JC: Cholera toxin induces sustained hyperexcitability in submucosal secretomotor neurons in guinea pig jejunum. Gastroenterology 2009, 136:299-308.
14. Hirata T, Keto Y, Nakata M, et al.: Effects of serotonin 5-HT3 receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats. Eur J Pharmacol 2008, 587:281-284.
15. Garfield AS, Heisler LK: Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 2009, 587:49-60.
16. Halford JC, HaErold JA, Boyland EJ, et al.: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27-55.
17. Bouwknecht JA, van der Gugten J, Hijzen TH, et al.: Male and female 5-HT1B receptor knockout mice have higher body weights than wildtypes. Physiol Behav 2001, 74:507-516.
18. Woolley ML, Bentley JC, Sleight AJ, et al.: A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41:210-219.
19. Nakamura K, Sato T, Ohashi A, et al.: Role of a serotonin precursor in development of gut microvilli. Am J Pathol 2008, 172:333-344.
20. Yadav VK, Ryu JH, Suda N, et al.: Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
21. Wouters MM, Gibbons SJ, Roeder JL, et al.: Exogenous serotonin regulates proliferation of interstitial cells of Cajal in mouse jejunum through 5-HT2B receptors. Gastroenterology 2007, 133:897-906.
22. Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657-1664.
23. Coleman N, Foley S, Dunlop SP, et al.: Abnormalities of serotonin metabolism and its relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006, 4:874-881.
24. Costedio MM, Coates MD, Danielson AB, et al.: Serotonin signaling in diverticular disease. J Gastrointest Surg 2008, 12:1439-1445.
25. Wang H, Steeds J, Motomura Y, et al.: CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007, 56:949-957.
26. Dunlop SP, Coleman NS, Blackshaw E, et al.: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349-357.
27. Van Lelyveld N, Ter Linde J, Schipper M, Samsom M: Serotonergic signaling in the stomach and duodenum of patients with gastroparesis. Neurogastroenterol Motil 2008, 20:448-455.
28. Van KerkhAven LA, Laheij RJ, Jansen JB: Meta-analysis: a functional polymorphism in the serotonin transporter gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:979-986.
29. Kapeller J, Houghton LA, Monnikes H, et al.: First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Molec Gen 2008, 17:2967-2977.
30. Carmani NA, Crim JL, Janoyan JJ, et al.: A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: Evidence from the least shrew. Brain Res 2009, 1248:40-58.
31. Nocito A, Dahm F, Jochum W, et al.: Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2008, 68:5152-5158.
32. Andresen V, Montori VM, Keller J, et al.: Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008, 6:545-555.
33. Chang L, Chey W, Harris L, et al.: Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006, 101:1069-1079.
34. Camilleri M: Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? Neurogastroenterol Motil 2007, 19:77-84.
35. De Maeyer JH, Lefebvre RA, Schuurkes JA: 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008, 20:99-112.
36. Li Y, Nie Y, Xie J, et al.: The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence of tegaserod treatment in Chinese patients. Dig Dis Sci 2007, 52:2942-2949.
37. Pasricha PJ: Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007, 132:2287-2290.
38. Camilleri M, Kerstens R, Rykx A, Vandeplassche L: A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008, 358:2344-2354.
39. Spiller RC, Meyers NL, Hickling RI: Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: An exploratory, multicenter, randomized, double-blind, placebo-controlled trial. Dig Dis Sci 2008, 53:3191-3200.
40. Kim HS, Choi EJ, Park H: The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 2008, 20:169-176.
41. EvangelistaPS: Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Invest Drugs 2007, 8:416-422.
42. Vera-Portocarrero LP, Ossipov MH, King T, Porreca F: Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 2008, 135:1369-1378.
43. Tack J, Broekaert D, Fischler B, et al.: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006, 55:1095-1103.
44. Halpert A, Dalton CB, Diamant NE, et al.: Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005, 100:664-671.
45. Jordan K, Schmoll HJ, Aapro MS: Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007, 61:162-175.
46. Smith BM, Thomsen WJ, Grottick AJ: The potential use of selective 5-HT2C agonists in treating obesity. Expert Opin Invest Drugs 2006, 15:257-266.
47. Heal DJ, Smith SL, Fisas A, et al.: Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharm Ther 2008, 117:207-231.
48. Xu W, Tanim H, Shapiro S, et al.: Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 2006, 7:301-308.